4.21
price down icon0.24%   -0.010
 
loading

Immuneering Corp Aktie (IMRX) Neueste Nachrichten

pulisher
Jul 22, 2025

What analysts say about Immuneering Corporation stockFree Stock Market Return Analysis - Autocar Professional

Jul 22, 2025
pulisher
Jul 19, 2025

What drives Immuneering Corporation stock priceFastest-growing stock picks - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 19, 2025

Analysts Set Immuneering Corporation (NASDAQ:IMRX) Target Price at $13.25 - Defense World

Jul 19, 2025
pulisher
Jul 18, 2025

Is Immuneering Corporation a good long term investmentSuperior stock growth - jammulinksnews.com

Jul 18, 2025
pulisher
Jul 15, 2025

What makes Immuneering Corporation stock price move sharplyTop Gaining Low Risk Assets - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Immuneering Corporation stock attracts strong analyst attentionShort Term Profit Focus - Newser

Jul 15, 2025
pulisher
Jul 10, 2025

Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up - Quantisnow

Jul 10, 2025
pulisher
Jul 09, 2025

Revolutionary Cancer Drug Gets Patent Protection Until 2042: Clinical Data Shows 94% Survival vs 67% Standard Care - Stock Titan

Jul 09, 2025
pulisher
Jul 07, 2025

Immuneering director Hausman buys IMRX stock worth $19,862 By Investing.com - Investing.com South Africa

Jul 07, 2025
pulisher
Jul 07, 2025

Immuneering (IMRX) chief people officer Neufeld buys $2498 in stock By Investing.com - Investing.com South Africa

Jul 07, 2025
pulisher
Jul 07, 2025

Immuneering director Hausman buys IMRX stock worth $19,862 - Investing.com

Jul 07, 2025
pulisher
Jul 01, 2025

Insider Buying: Thomas Schall Acquires Additional Shares of Immu - GuruFocus

Jul 01, 2025
pulisher
Jun 27, 2025

Immuneering (IMRX) Soars 10.66% on Positive Trial Data, Insider Buying - AInvest

Jun 27, 2025
pulisher
Jun 26, 2025

At $3.02 Price, Immuneering Corp (IMRX) Is Sitting And Waiting - Stocksregister

Jun 26, 2025
pulisher
Jun 25, 2025

Jefferies raises Immuneering price target to $3.50 from $1.50 on cancer data - Investing.com

Jun 25, 2025
pulisher
Jun 24, 2025

Immuneering (IMRX) CBO Brakewood buys $4804 in shares - Investing.com

Jun 24, 2025
pulisher
Jun 23, 2025

Immuneering (IMRX) director Feinberg buys $63k in shares - Investing.com

Jun 23, 2025
pulisher
Jun 20, 2025

Immuneering (IMRX) CEO Zeskind buys $50k+ in shares - Investing.com

Jun 20, 2025
pulisher
Jun 19, 2025

Immuneering (NASDAQ:IMRX) Receives Buy Rating from Needham & Company LLC - Defense World

Jun 19, 2025
pulisher
Jun 18, 2025

Immuneering (IMRX) Target Price Raised by Mizuho Analyst | IMRX Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Chardan Capital Maintains Buy Rating on IMRX with $13 Price Targ - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Metric Deep Dive: Understanding La Rosa Holdings Corp (LRHC) Through its Ratios - DWinneX

Jun 18, 2025
pulisher
Jun 18, 2025

Financial Analysis: TNL Mediagene (TNMG)’s Ratios Unveil Key Insights - DWinneX

Jun 18, 2025
pulisher
Jun 18, 2025

Immuneering (IMRX) Price Target Raised by Mizuho Following Positive Trial Data | IMRX Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Immuneering stock price target raised to $10 at Mizuho on cancer drug data - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Immuneering’s Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally - Investing.com India

Jun 18, 2025
pulisher
Jun 18, 2025

Immuneering's Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally - MENAFN.com

Jun 18, 2025
pulisher
Jun 17, 2025

Immuneering’s atebimetinibin shows positive survival data in pancreatic cancer - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Immuneering stock rises after positive pancreatic cancer trial data - Investing.com

Jun 17, 2025
pulisher
Jun 17, 2025

Immuneering (IMRX) Reports Promising Phase 2a Trial Results for Pancreatic Cancer Treatment | IMRX Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Pancreatic Cancer Breakthrough: New Drug Shows 94% Survival Rate vs 67% Standard Care in Phase 2a Trial - Stock Titan

Jun 17, 2025
pulisher
Jun 17, 2025

Immuneering Stock Soars 25.74% on Promising Cancer Trial Results - AInvest

Jun 17, 2025
pulisher
Jun 16, 2025

Immuneering Corp holds annual stockholder meeting By Investing.com - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

Immuneering Corp holds annual stockholder meeting - Investing.com Australia

Jun 16, 2025
pulisher
Jun 16, 2025

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - The Manila Times

Jun 16, 2025
pulisher
Jun 16, 2025

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - GlobeNewswire Inc.

Jun 16, 2025
pulisher
Jun 13, 2025

Two Sigma Investments LP Purchases 10,126 Shares of Immuneering Co. (NASDAQ:IMRX) - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

Immuneering Co. (NASDAQ:IMRX) Stock Position Reduced by Millennium Management LLC - Defense World

Jun 12, 2025
pulisher
Jun 06, 2025

Immuneering’s (IMRX) Buy Rating Reaffirmed at Needham & Company LLC - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Needham Maintains Buy Rating on IMRX with Price Target of $9.00 - GuruFocus

Jun 05, 2025
pulisher
May 29, 2025

Full Immuneering Leadership Team Reveals Latest Pipeline Updates at Prestigious Jefferies Conference - Stock Titan

May 29, 2025
pulisher
May 29, 2025

Immuneering Corporation to Present at Jefferies Global Healthcare Conference on June 5, 2025 - Nasdaq

May 29, 2025
pulisher
May 15, 2025

‘Take the Plunge,’ Says Top Investor About Intel Stock - The Globe and Mail

May 15, 2025
pulisher
May 07, 2025

Oppenheimer Adjusts Price Target for Immuneering (IMRX) to $21.0 - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Immuneering (IMRX) Price Target Adjusted by Oppenheimer Analyst - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Immuneering (IMRX) Price Target Adjusted by Oppenheimer Analyst | IMRX Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

21,432 Shares in Immuneering Co. (NASDAQ:IMRX) Acquired by Marshall Wace LLP - Defense World

May 07, 2025
pulisher
May 07, 2025

Oppenheimer Adjusts Price Target for Immuneering (IMRX) to $21.00 | IMRX Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Immuneering Corp. Reports Promising Q1 2025 Results - TipRanks

May 07, 2025
pulisher
May 06, 2025

Immuneering (IMRX) Stock Rating and Price Target Update | IMRX S - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Immuneering reports Q1 EPS (42c), consensus (58c) - TipRanks

May 06, 2025
pulisher
May 05, 2025

Immuneering Corp SEC 10-Q Report - TradingView

May 05, 2025
pulisher
May 05, 2025

Immuneering Reports Breakthrough: Cancer Drug Achieves 13-Month Survival in Late-Stage Pancreatic Cancer Patient - Stock Titan

May 05, 2025
pulisher
May 04, 2025

IMRXImmuneering Corp Latest Stock News & Market Updates - Stock Titan

May 04, 2025
pulisher
May 04, 2025

Why imrx price is going down right now - AInvest

May 04, 2025
pulisher
May 01, 2025

Charting the Course: Immuneering Corp’s IMRX Stock Prospects - investchronicle.com

May 01, 2025
$22.84
price up icon 4.79%
$36.02
price down icon 0.24%
$102.69
price down icon 0.29%
$27.91
price up icon 5.14%
$113.56
price up icon 1.86%
biotechnology ONC
$295.56
price down icon 0.03%
Kapitalisierung:     |  Volumen (24h):